Signe M. Christensen,Nikolaj Dam Mikkelsen,Miriam Frieden,Henrik Frydenlund Hansen,Troels Koch,Daniel Sejer Pedersen,Christoph Rosenbohm,Charlotte Albaek Thrue,Majken Westergaard
申请号：
US15619134
公开号：
US09994850B2
申请日:
2017.06.09
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
